News & Articles

Survey finds fear and misconceptions around hepatitis discourage testing, with more than half of respondents assuming they are not at risk

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT)

Clinical mass spectrometry testing offers sensitivity and specificity, providing clinicians with additional diagnostic insights

The PATHWAY HER2 (4B5) test helps identify patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA

Roche’s Elecsys Amyloid Plasma Panel shows high accuracy in ruling out Alzheimer's, offering new hope for early and less invasive diagnostics

Roche obtains CE certification for VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

OCREVUS ZUNOVO has the potential to expand treatment options to centers without IV infrastructure or with IV constraints

The cobas c 703 and cobas ISE neo analytical units deliver greater efficiency and capacity to laboratories

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

The Roche Diagnostics Tina-quant Lp(a) assay measures lipoprotein (a) in a person’s bloodstream

Expanding access and screening options to help eliminate cervical cancer with one of the first HPV self-collection solutions in the US

Supporting earlier Alzheimer's disease diagnosis

The cobas Malaria test is the first FDA-approved molecular test to screen US blood donors for malaria

The test detects T-cell response, which may play an important role in determining if immune protection has been achieved

The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science

The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study

The three new respiratory test panels on cobas 6800/8800 Systems in CE markets will help identify multiple pathogens with overlapping symptoms in patients

Using cancer biomarkers, the VENTANA MMR RxDx Panel helps determine which tumor patients may benefit from GSK immunotherapy

The drug aims to treat patients with myelodysplastic syndromes

The authorization enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalized adult and pediatric patients

The test will be widely available to individuals through pharmacies and other locations in accordance with local guidelines and testing strategies

First commercial test will enable expedited coronavirus testing to meet urgent medical needs